Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years' single-center real-world experience.

Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.